ES2394952T3 - Derivados de axapéptido como inhibidores de la proteasa VIH - Google Patents
Derivados de axapéptido como inhibidores de la proteasa VIH Download PDFInfo
- Publication number
- ES2394952T3 ES2394952T3 ES11155667T ES11155667T ES2394952T3 ES 2394952 T3 ES2394952 T3 ES 2394952T3 ES 11155667 T ES11155667 T ES 11155667T ES 11155667 T ES11155667 T ES 11155667T ES 2394952 T3 ES2394952 T3 ES 2394952T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- pharmaceutically acceptable
- composition
- acceptable salt
- efavirenz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93420107P | 2007-06-12 | 2007-06-12 | |
| US934201P | 2007-06-12 | ||
| US6762708P | 2008-02-29 | 2008-02-29 | |
| US67627P | 2008-02-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2394952T3 true ES2394952T3 (es) | 2013-02-07 |
Family
ID=39730784
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08252023T Active ES2356334T3 (es) | 2007-06-12 | 2008-06-12 | Derivados de azapéptidos como inhibidores de la proteasa vih. |
| ES11155667T Active ES2394952T3 (es) | 2007-06-12 | 2008-06-12 | Derivados de axapéptido como inhibidores de la proteasa VIH |
| ES09075359T Active ES2395137T3 (es) | 2007-06-12 | 2008-06-12 | Derivados de azapéptidos como inhibidores de la proteasa VIH |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08252023T Active ES2356334T3 (es) | 2007-06-12 | 2008-06-12 | Derivados de azapéptidos como inhibidores de la proteasa vih. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09075359T Active ES2395137T3 (es) | 2007-06-12 | 2008-06-12 | Derivados de azapéptidos como inhibidores de la proteasa VIH |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US20090036357A1 (show.php) |
| EP (3) | EP2322509B1 (show.php) |
| JP (1) | JP2010529196A (show.php) |
| KR (2) | KR20120029480A (show.php) |
| CN (2) | CN101711237B (show.php) |
| AR (1) | AR066972A1 (show.php) |
| AT (2) | ATE447554T1 (show.php) |
| AU (1) | AU2008267048C1 (show.php) |
| BR (2) | BRPI0813911A2 (show.php) |
| CA (1) | CA2692028C (show.php) |
| CO (1) | CO6241121A2 (show.php) |
| CY (1) | CY1109766T1 (show.php) |
| DE (1) | DE602008000255D1 (show.php) |
| DK (1) | DK2003120T3 (show.php) |
| ES (3) | ES2356334T3 (show.php) |
| HR (1) | HRP20100065T1 (show.php) |
| MX (1) | MX2009013565A (show.php) |
| PL (1) | PL2003120T3 (show.php) |
| PT (1) | PT2003120E (show.php) |
| RS (1) | RS51226B (show.php) |
| RU (2) | RU2448958C2 (show.php) |
| SI (1) | SI2003120T1 (show.php) |
| TW (1) | TW200908970A (show.php) |
| WO (1) | WO2008156632A1 (show.php) |
| ZA (1) | ZA200909079B (show.php) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008103899A1 (en) * | 2007-02-23 | 2008-08-28 | Auspex Pharmaceuticals, Inc. | Preparation and utility of non-nucleoside reverse transcriptase inhibitors |
| CA2692028C (en) | 2007-06-12 | 2013-06-04 | Concert Pharmaceuticals, Inc. | Azapeptide derivatives |
| WO2010041241A2 (en) * | 2008-10-06 | 2010-04-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Hiv-1 integrase derived peptides and compositions |
| WO2010132663A1 (en) * | 2009-05-13 | 2010-11-18 | Concert Pharmaceticals, Inc. | Pegylated azapeptide derivatives as hiv protease inhibitors |
| WO2010135424A1 (en) * | 2009-05-19 | 2010-11-25 | Glaxosmithkline Llc | Chemical compounds |
| AU2010338425B2 (en) | 2009-12-21 | 2015-07-23 | Janssen Sciences Ireland Uc | Degradable removable implant for the sustained release of an active compound |
| WO2011080562A1 (en) | 2009-12-29 | 2011-07-07 | Hetero Research Foundation | Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals |
| PE20150928A1 (es) | 2011-06-20 | 2015-06-26 | Lundbeck & Co As H | 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia |
| CN106543073A (zh) * | 2015-09-17 | 2017-03-29 | 宁波杰尔盛化工有限公司 | 2-[4-（2-吡啶基）苄基]-肼羧酸叔丁酯的制备方法 |
| DK3383397T3 (da) * | 2015-12-02 | 2021-11-08 | Merck Sharp & Dohme | Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin |
| JP7034084B2 (ja) | 2016-03-28 | 2022-03-11 | インサイト・コーポレイション | Ｔａｍ阻害剤としてのピロロトリアジン化合物 |
| JOP20180009A1 (ar) | 2017-02-06 | 2019-01-30 | Gilead Sciences Inc | مركبات مثبط فيروس hiv |
| WO2019025250A1 (en) | 2017-08-04 | 2019-02-07 | Basf Se | SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI |
| CA3077308A1 (en) | 2017-09-27 | 2019-04-04 | Incyte Corporation | Salts of pyrrolotriazine derivatives useful as tam inhibitors |
| EA202190153A1 (ru) | 2018-06-29 | 2021-04-09 | Инсайт Корпорейшн | Составы ингибитора axl/mer |
| TWI766172B (zh) | 2018-07-30 | 2022-06-01 | 美商基利科學股份有限公司 | 抗hiv化合物 |
| AU2021230385A1 (en) | 2020-03-06 | 2022-09-22 | Incyte Corporation | Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors |
| JP2023522210A (ja) * | 2020-04-16 | 2023-05-29 | ザ メディカル カレッジ オブ ウィスコンシン インク | 気道逆流の治療のためのｈｉｖプロテアーゼ阻害剤のエアロゾル化製剤 |
| CN115385983A (zh) * | 2022-01-11 | 2022-11-25 | 嘉兴安谛康生物科技有限公司 | 氮杂双环类化合物及其制备方法、药物组合物和用途 |
| WO2024249517A1 (en) | 2023-05-31 | 2024-12-05 | Gilead Sciences, Inc. | Anti-hiv compounds |
| CN116987024A (zh) * | 2023-08-01 | 2023-11-03 | 浙江荣耀生物科技股份有限公司 | 一种阿扎那韦中间体的制备方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3689976T2 (de) | 1985-05-15 | 1995-03-16 | Wellcome Found | Therapeutische Nucleoside und deren Herstellung. |
| GB8815265D0 (en) * | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
| US5539122A (en) * | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| GB9009861D0 (en) | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
| DE674513T1 (de) | 1992-12-29 | 1996-01-18 | Abbott Lab | Inhibitoren der retroviralen protease. |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| WO1995026325A2 (en) | 1994-03-25 | 1995-10-05 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US5849911A (en) | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
| TW409125B (en) * | 1996-04-22 | 2000-10-21 | Novartis Ag | Antivirally active heterocyclic azahexane derivatives |
| WO1997046514A1 (en) | 1996-05-31 | 1997-12-11 | Novartis Ag | Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues |
| US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| GB9914821D0 (en) | 1999-06-24 | 1999-08-25 | Glaxo Group Ltd | Compounds |
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| DE60001623T2 (de) * | 1999-12-03 | 2003-12-18 | Pfizer Products Inc., Groton | Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel |
| BR0209325A (pt) | 2001-05-03 | 2004-07-20 | Hoffmann La Roche | Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo |
| US6737042B2 (en) | 2001-05-24 | 2004-05-18 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| US20030045501A1 (en) | 2001-08-31 | 2003-03-06 | Bechtold Clifford M. | Use of atazanavir in HIV therapy |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| WO2005027855A2 (en) | 2003-02-21 | 2005-03-31 | Jarrow Formulas, Inc. | Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors |
| US20050131017A1 (en) | 2003-12-11 | 2005-06-16 | Degoey David A. | HIV protease inhibiting compounds |
| US20050148523A1 (en) | 2003-12-15 | 2005-07-07 | Colonno Richard J. | Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor |
| US7829720B2 (en) * | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
| AU2005270124B2 (en) * | 2004-07-06 | 2011-09-08 | Abbvie Inc. | Prodrugs of HIV protease inhibitors |
| KR20070083839A (ko) | 2004-09-29 | 2007-08-24 | 코디스 코포레이션 | 안정한 무정형 라파마이신 유사 화합물의 약학적 투약 형태 |
| US20070259894A1 (en) | 2004-12-03 | 2007-11-08 | Kelem Kassahun | Use of Atazanavir for Improving the Pharmacokinetics of Drugs Metabolized by Ugt1a1 |
| BRPI0617987A2 (pt) * | 2005-10-06 | 2011-08-16 | Auspex Pharmaceuticals Inc | composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| JO2630B1 (en) | 2006-04-13 | 2012-06-17 | نوفارتيس ايه جي | Organic compounds |
| CA2661404A1 (en) * | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| CA2692028C (en) * | 2007-06-12 | 2013-06-04 | Concert Pharmaceuticals, Inc. | Azapeptide derivatives |
| US20090076097A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched atazanavir |
| WO2010132663A1 (en) | 2009-05-13 | 2010-11-18 | Concert Pharmaceticals, Inc. | Pegylated azapeptide derivatives as hiv protease inhibitors |
-
2008
- 2008-06-12 CA CA2692028A patent/CA2692028C/en not_active Expired - Fee Related
- 2008-06-12 WO PCT/US2008/007331 patent/WO2008156632A1/en not_active Ceased
- 2008-06-12 KR KR1020127003399A patent/KR20120029480A/ko not_active Withdrawn
- 2008-06-12 BR BRPI0813911-3A patent/BRPI0813911A2/pt not_active IP Right Cessation
- 2008-06-12 AU AU2008267048A patent/AU2008267048C1/en not_active Ceased
- 2008-06-12 CN CN2008800216013A patent/CN101711237B/zh not_active Expired - Fee Related
- 2008-06-12 PT PT08252023T patent/PT2003120E/pt unknown
- 2008-06-12 EP EP11155667A patent/EP2322509B1/en active Active
- 2008-06-12 EP EP08252023A patent/EP2003120B9/en active Active
- 2008-06-12 ES ES08252023T patent/ES2356334T3/es active Active
- 2008-06-12 RU RU2010100821/04A patent/RU2448958C2/ru not_active IP Right Cessation
- 2008-06-12 DK DK08252023.0T patent/DK2003120T3/da active
- 2008-06-12 CN CN2011102869075A patent/CN102424668A/zh active Pending
- 2008-06-12 TW TW097122018A patent/TW200908970A/zh unknown
- 2008-06-12 AT AT08252023T patent/ATE447554T1/de active
- 2008-06-12 AT AT09075359T patent/ATE536343T1/de active
- 2008-06-12 BR BRPI0823520-1A patent/BRPI0823520A2/pt not_active IP Right Cessation
- 2008-06-12 AR ARP080102501A patent/AR066972A1/es unknown
- 2008-06-12 EP EP09075359A patent/EP2116532B1/en active Active
- 2008-06-12 ES ES11155667T patent/ES2394952T3/es active Active
- 2008-06-12 PL PL08252023T patent/PL2003120T3/pl unknown
- 2008-06-12 RS RSP-2010/0034A patent/RS51226B/sr unknown
- 2008-06-12 ES ES09075359T patent/ES2395137T3/es active Active
- 2008-06-12 SI SI200830012T patent/SI2003120T1/sl unknown
- 2008-06-12 JP JP2010512186A patent/JP2010529196A/ja active Pending
- 2008-06-12 KR KR1020107000675A patent/KR101185899B1/ko not_active Expired - Fee Related
- 2008-06-12 DE DE602008000255T patent/DE602008000255D1/de active Active
- 2008-06-12 US US12/157,712 patent/US20090036357A1/en not_active Abandoned
- 2008-06-12 MX MX2009013565A patent/MX2009013565A/es active IP Right Grant
-
2009
- 2009-12-11 CO CO09141805A patent/CO6241121A2/es not_active Application Discontinuation
- 2009-12-18 ZA ZA2009/09079A patent/ZA200909079B/en unknown
-
2010
- 2010-02-03 CY CY20101100099T patent/CY1109766T1/el unknown
- 2010-02-03 HR HR20100065T patent/HRP20100065T1/hr unknown
- 2010-04-06 US US12/755,184 patent/US8158805B2/en not_active Expired - Fee Related
-
2012
- 2012-01-19 RU RU2012101881/04A patent/RU2012101881A/ru not_active Application Discontinuation
- 2012-03-02 US US13/411,089 patent/US8258309B2/en not_active Expired - Fee Related
- 2012-08-27 US US13/595,511 patent/US20130041156A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2394952T3 (es) | Derivados de axapéptido como inhibidores de la proteasa VIH | |
| ES2425183T3 (es) | Derivados de oxazolidinonas sustituidas | |
| US20090131363A1 (en) | Deuterated darunavir | |
| KR102132574B1 (ko) | 트라이사이클릭 자이라제 억제제 | |
| WO2009148600A2 (en) | Deuterated lysine-based compounds | |
| ES2406479T3 (es) | Derivado deuterado de 4-oxoquinolina para el tratamiento de la infección por VIH | |
| US20130040914A1 (en) | Prodrugs of an hiv reverse transcriptase inhibitor | |
| EP2163553B1 (en) | Arene connected polyamine macroring derivatives, preparation methods and pharmaceutical uses thereof | |
| WO2010132663A1 (en) | Pegylated azapeptide derivatives as hiv protease inhibitors | |
| HK1154862A (en) | Azapeptide derivatives as hiv protease inhibitors | |
| HK1127345B (en) | Azapeptide derivatives as hiv protease inhibitors | |
| AU2012216511A1 (en) | Azapeptide derivatives | |
| HK1136576B (en) | Azapeptide derivatives as hiv protease inhibitors | |
| WO2021257669A1 (en) | Synthesis of substituted arylmethylureas, analogues, and crystalline forms thereof and methods of using same | |
| HK1138580B (en) | Arene connected polyamine macroring derivatives, preparation methods and pharmaceutical uses thereof |